Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1995; 74(01): 025-035
DOI: 10.1055/s-0038-1642648
DOI: 10.1055/s-0038-1642648
Special Colloquium
The Fibrinolytic System: from Petri Dishes to Genetic Engineering
Authors
Further Information
Publication History
Publication Date:
09 July 2018 (online)
-
References
- 1 Denys J, De Marbaix H. Les peptonisations provoquees par le chlorofoime. Cellule 1889; 5: 197-197
- 2 Dastre A. Fibrinolyse dans le sang. Arch Norm Pathol 1893; 5: 661-661
- 3 Nolf P. Contribution a Fetude de la coagulation du sang V. La fibrinolyse. Arch Int Physiol 1908; 6: 306-359
- 4 Yudin SS. Transfusion of cadaver blood. JAMA 1936; 106: 997-999
- 5 Fleisher MS, Loeb L. On tissue fibrinolysis. J Biol Chem 1915; 21: 477-501
- 6 Astrup T. Fibrinolysis in the organism. Blood 1956; 11: 781-806
- 7 Tillett WS, Gamer RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 56: 485-502
- 8 Tillett WS, Gamer RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933; 58: 485-502
- 9 Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol 1941; 42: 109-116
- 10 Tagnon HJ, Davidson CS, Taylor FHL. The coagulation defect in hemophilia: a comparison of the proteolytic activity of chloroform preparations of hemophilic and normal plasma. J Clin Invest 1943; 22: 127-134
- 11 Christensen LR. Streptococcal fibrinolysis: A proteolytic reaction due to a serum enzyme activated by streptococcal fibrinolysis. J Gen Physiol 1945; 28: 263-383
- 12 MacFarlane RG, Biggs R. Fibrinolysis: its mechanism and significance. Blood 1948; 3: 1167-1187
- 13 Wun TC, Schleuning WD, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
- 14 Lassen M. Heat denaturation of plasminogen in the fibrin plate method. Acta Physiol Scandinav 1952; 27: 371-376
- 15 Claeson G, Aurell L, Friberger P, Gustavsson S, Karlson G. Designing of peptide substrates. Different approaches amplified by new chromogenic substrates for kallikrein and urokinase. Haemostasis 1978; 7: 62-68
- 16 Christensen LR. Protamine purification of streptokinase and effect of pH and temperature on reversible inactivation. J Gen Physiol 1947; 30: 465-473
- 17 Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptoccocal deoxyribonuclease on fibrinous, purulent, and sanguineous pleural exudations. J din Invest 1949; 28: 173-190
- 19 Johnson AJ, Tillett WS. Lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med 1952; 95: 449-464
- 20 Cliffton EE, Cannamela DA, Grossi C. In vivo studies of human plasmin. Intravenous injection in dogs and rabbits. J Appl Physiol 6: 143-150 1953;
- 21 Johnson AJ, McCarty WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J din Invest 1959; 38: 1627-1643
- 22 Guest MM, Celander DR. Urokinase: Physiologic activatorof profibrinolysis. Tex Rep Biol Med 1961; 19: 89-105
- 23 White WF, Barlow GH, Mozen MM. The isolation and characterization of plasminogen activators (urokinase) from human urine. Biochemistry 1966; 5: 2160-2169
- 24 Barlow GH. Urinary and kidney cell plasminogen activator (urokinase). In: Lorand L. ed. Methods in Enzymology Vol.45. San Diego; CA: Academic Press: 1976: 239-244
- 25 Harpel PC, Chang TS, Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. J Biol Chem 1985; 260: 4432-4440
- 26 Rakoczi I, Wiman B, Collen D. On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. Biochim Biophys Acta 1978; 540: 295-300
- 27 Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. Development of urokinase as a thrombolytic agent: maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 1965; 654: 713-731
- 28 Gross R, Haiti W, Kloss G, Rahn B. Thrombolyse durch Infusionen hochgereinigter Streptokinase. Erfahrungen und Untersuchungen an den ersten 50 Kranken. Dtsch Med Wschr 1960; 85: 2129-2135
- 29 Verstraete M, Amery A, Veimylen J. Feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusion. Brit Med J 1963; 1: 1499-1504
- 30 Schmutzler R, Koller F. Thrombolytic treatment of acute peripheral and venous occlusions. Angiologica 1968; 5: 119-128
- 31 Fletcher AP, Alkjaersig M, Sherry S. The clearance of heterologous protein from the circulation of normal and immunized man. J din Invest 1958; 37: 1306-1315
- 32 Amery A, Maes H, Veimylen J, Verstraete M. The streptokinase reactivity test. I Standardization. Thromb Diath Haemorrh 1963; 9: 175-188
- 33 Verstraete M, Amery A, Veimylen J. The feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusions. Thromb Diathes Haemonh 1962; 7: 211-236
- 34 Verstraete M, Tytgat G, Amery A, Veimylen J. Thrombolytic therapy with streptokinase using a standard dosage. Thromb Diath Haemorrh 1966; 16: 494-500
- 35 Urokinase Pulmonary Embolism Trial Study Group:. Urokinase pulmonary embolism trial: phase I results. J Am Med Ass 1970; 214: 2163-2172
- 36 Urokinase-Streptokinase Pulmonary Embolism Trial Study Group:. Phase II results:. a national cooperative trial. JAMA 1974; 229: 1606-1613
- 37 Poliwoda H, Schroder R, Heckner F. Erste Erfahrungen mit der fibrinolytisehen Therapie beim Akuten Myocardinfarct. Dtsch Med Wschr 1963; 88: 218-224
- 38 Amery A, Roeber G, Vermeulen HJ, Verstraete M. Single-blind randomised multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction. Acta Med Scand Suppl 1969; 505: 5-35
- 39 European Cooperative Study Group for Streptokinase Treatment in Acute Myocardial Infarction:. Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797-797
- 40 Verstraete M, Van de Loo J, Jesdinsky HJ. Streptokinase in acute myocardial infarction. Acta Med Scand Suppl 198;. 648: 7117-7117
- 41 DeWood MA, Spores J, Notske R, Lowell T, Mouser T, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902
- 42 Rijken DC, Wijngaards G, Zaal-De JongM, Welbergen J. Purification and partial characterization of plasminogen activatorfrom human uterine tissue. Biochim Biophys Acta 1979; 580: 140-153
- 43 Wilson EL, Becker ML B, Hoal EG, Dowdle EB. Molecular species of plasminogen activators secreted by normal and neoplastic human cells. Cancer Res 1980; 40: 933-938
- 44 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 156: 7035-7041
- 45 Weimar W, Stibbe J, van Seyen AJ, Billiau A, DeSomer P, Collen D. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981; 2: 1018-1020
- 46 Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KAA, de Geest H, Verstraete M, Collen D, Sobel B. Clot-selective coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. NEngl J Med 1984; 310: 609-613
- 47 Opdenakker G, Weening H, Collen D, Billiau A, DeSomer P. Messenger RNA for human tissue plasminogen activator. Eur J Biochem 1982; 121: 269-274
- 48 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in£. coli. Nature 1983; 201: 214-221
- 49 Collen D, Stassen JM, Marafino Jr BJ, Builder S, DeCock F, Ogez J, Tajiri D, Pennica D, Bennett WF, Salwa J, Hoyng CF. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J Pharm Exp Ther 1984; 231: 146-152
- 50 Bergmann SR, Fox KA A, Ter-Pogossian MM, Sobel BE, Collen D. Clotselective coronary thrombolysis with tissue-type plasminogen activator Science. 1983; 220: 1181-1183
- 51 Van de Werf F, Bergmann SR, Fox KAA, DeGeest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984; 69: 605-610
- 52 Gold HK, Fallon JT, Yasuda T, Khaw BA, Newell JB, Leinbach RC, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E, Collen D. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 1984; 70: 700-707
- 53 Flameng W, VandeWerf F, Vanhaecke J, Verstraete M, Collen D. Coronary thrombolysis and infarct size reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates. J Clin Invest 1985; 75: 84-90
- 54 Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasudat BulkleyB H, Robison AK, Hutter AM, Bell WR, Sparado JJ, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator A prospective, randomized, placebo-controlled trial. Circulation 1984; 70: 1012-1017
- 55 Pietrolungo JF, Topol EJ. Thrombolytic therapy for acute myocardial infarction in thrombolytic therapy for peripheral vascular disease AJ Comerota, editor J.B. Lippincott Company; Philadelphia: 1995: 349-398
- 56 Bernik MB, Oiler EP. Plasminogen activator and proactivator (urokinase precursor) in lung cultures. J Am Med Assoc 1976; 31: 465-472
- 57 Nolli ML, Sarubbi E, Corti A, Rabbiati F, Soffientini A, Blasi F, Parenti F, Cassani G. Production and characterization of human recombinant single chain urokinase-type plasminogen activator from mouse cells. Fibrinolysis 1989; 3: 101-106
- 58 Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens G, Heyneker HL. Cloning and expression of the gene for pro-urokmase in Escherichia coli. Biotechnology 1985; 3: 923-929
- 59 Eaton DL, Scott RW, Baker JB. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem 1984; 259: 6241-6247
- 60 Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltoft K, Zeuthen J, Dano K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinty chromatography with monoclonal antibody. Biochemistry 1982; 24: 6410-6415
- 61 Steffens GJ, Guenzler WA, Oetting F, Frankus E, Flohe L. The complete amino acid sequence of low molecular mass urokinase from human urine Hoppe-Seyler’s Z Physiol Chem. 1982; 363: 1043-1058
- 62 Gurewich V, Pannell R, Lowe S. Effective and fibrin-specific clot lysis by a zymogen precursor forni of urokinase (pro-urokinase)- a study in vitro and in two animal species. J Clin Invest 1984; 73: 1731-1734
- 63 Pannell R, Gurewich V. The activation of plasminogen by single chain urokinase or by two-chain urokinase - a demonstration that single chain urokinase has a low catalytic activity (prourokinase). Blood 1987; 69: 22-26
- 64 Collen D, De Cock F, Lijnen HR. Biological and thrombolytic properties of proenzyme and active forms ofhuman urokinase. II. Turnover of natural and recombinant urokinase in rabbits and squirrel monkeys. Thromb Haemost 1984; 52: 24-26
- 65 Stump DC, Lijnen HR, Collen D. Purification and characterization of single-chain urokinase-type plasminogen activatorfrom human cell cultures. J Biol Chem 1986; 261: 1274-1278
- 66 Gruppo Italiano per lo Studio della Streptochinasi nelT Infarcto Miocardico (GISSI-2):. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71
- 67 The International Study Group:. In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-79
- 68 ISIS-3 (Third International Study of Infarct Survival) Collaborative Group:. A randomized trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-777
- 69 Sobel BE, Collen D. Questions unresolved by the third International Study of infarct survival. Am J Cardiol 1992; 70: 385-389
- 70 Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W, Limbourg P, Merx W, Haerten K. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplate results of the rt-PA-APSAC patency study (TAPS). J Am CoE Cardiol 1992; 19: 885-891
- 71 Grines CL, Nissen SE, Booth DC, Gurley JC, CheUiah N, Wolf R, Blankenship J, Branco MC, Bennett K, DeMaria AN. the Kentucky Acute Myocardial Infarction Trial (KAMIT) Group: A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Circulation 1991; 84: 540-549
- 72 deBono DP, Simoons ML, Tijssen J, Arnold AER, Betriu A, Burgersdijk C, Lopez BescosL, MueUer E, Pfisterer M, Vande WerfF, Zylstra F, Verstraete M. for the European Cooperative Study Group: Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group. Br Hear J 1992; 67: 122-128
- 73 The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682
- 74 The GUSTO Angiographic Investigators:. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622
- 75 Andreotti F, Kluft C, Hackett DR, Davies GJ, Maseri A. Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator. Lancet 1993; 342: 937-938
- 76 Purvis JA, Trouton TG, Robert MJD, McKeown P, MulhoEand MG, DalzeE GWN, Wilson CM, Patterson GC, Webb SW, Khan MM, CampbeU NPS, Adgey J. Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. J Am CoE Cardiol 1994; 23: 6-10
- 77 Lijnen HR, CoEen D. Strategies for the improvement of thrombolytic agents. Thromb Haemostas 1991; 66: 88-110
- 78 Collen D, deBono DP, Lijnen HR, Pannekoek H. Development of novel thrombolytic agents. J Int Med 1994; 236: 433-437
- 79 Madison EL. Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis. Fibrinolysis 1994’ 8: 221-236
- 80 Kohnert U, Rudolph R, Verheijen JH, Weening-Verhoeff EJD, Stem A, Opitz U, Martin U, Lili H, Prinz H, Lechner M, Kresse GB, Buckel P. FischerS: Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Prot Engineer 1992; 5: 93-100
- 81 Sturzebecher J, Neumann U, Kohnert U, Kresse GB. FischerS: Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Prot Sc 1991; 1: 1007-1013
- 82 Hajjar KA: The endothelial cell tissue plasminogen activator receptor. J Biol Chem 1991; 266: 21962-21970
- 83 Martin U, Fischer S, Kohnert U, Opitz U, Rudolph R, Sponer G, Stem A, Strein K. Thrombolysis with an Escherichia coli-produced recombinant plasminogen activator (BM 06.022) in the rabbit model of jugular vein thrombosis. Thromb Haemostas 1991; 65: 560-564
- 84 Martin U, van Mollendorf E, Akpan W, Kientsch-Engel R, Kaufmann B, Neugebauer G. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Phaimacol Ther 1991; 50: 429-436
- 85 Martin U, Kohler J, Sponer G, Strein K. Pharmacokinetics of the novel recombinant plasminogen activator BM 06.022 in rats, dogs, and nonhuman primates. Fibrinolysis 1992; 6: 39-43
- 86 Muller M, Haerer W, Ellbriick D, Martin U, Konig R, Seifried E. for the GRECO Study Group: Pharmacokinetics and effects on the hemostatic system of bolus application of a novel recombinant plasminogen activator in AMI patients. Fibrinolysis 6. Suppl 02 26. Abstract 63 1992
- 87 Martin U, Bader R, Bohm E, Kohnert U, van Mollendorf E, Fischer S, Sponer G. BM 06 022 a novel recombinant plasminogen activator. Cardiovasc Drag Rev 1993; 11: 299-311
- 88 Neuhaus K-L, von Essen R, Vogt A, Tebbe U, Rustige J, Wagner HJ, Appel KF, Stienen V, Konig R, Meyer-Sabellek W. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German recombinant plasminogen activator study. J Am Coll Cardiol 1994; 24: 55-60
- 89 Tebbe U, von Essen R, Smolarz A, Limbourg P, Rox J, Rustige J, Vogt A, Wagner J, Meyer-Sabellek W, Neuhaus KL. Open, noncontrolled dosefinding study with a novel recombinant plasminogen activator(BM 06.022) given as a double bolus in patients with acute myocardial infarction. Am J Cardiol 1993; 72: 518-524
- 90 Smalling RW, Bode C, Kalbfleisch J, Sen P, Limbourg F, Forycki G, Habib G, Feldman R, Hohnloser S, Seals A. for the RAPID Investigators: Improvement of global and regional LV function by the bolus administration of recombinant plasminogen activator (r-PA) in acute myocardial infarction: a comparison with standard dose alteplase Circulation. 1994; 90: 562 (abstr 3029)
- 91 Lijnen HR, Collen D. Development of chimeric tissue-type/urokinase-type plasminogen activators for thrombolytic therapy. Curr Opin Invest New Drugs 1993; 2: 495-504
- 92 Collen D, Stassen JM, Demarsin E, Kieckens L, Lijnen HR, Nelles L. Pharmacokinetics and thrombolytic properties of chimaeric plasminogen activators consisting of the NH2-terminal region of human tissue-type plasminogen activator and the COOH-terminal region of human single chain urokinase-type plasminogen activator. J Vase Med Biol 1989; 1: 234-240
- 93 Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators. Circulation 1991; 84: 1216-1234
- 94 Vande WerfF, Lijnen HR, Collen D. Coronary thrombolysis withK1 K«P , a chimeric tissue-type and urokinase-type plasminogen activator. Afeasibility study in six patients with acute myocardial infarction. Coron Art Dis 1993 4: 929-933
- 95 Gardell SJ, Duong LT, Diehl RE, Yoik JD, Hare TR, Register RB, Jacobs JW, Dixon RAF, Friedman PA. Isolation, characterizaton, and cDNA cloning of a vampire bat salivaiy plasminogen activator. J Biol Chem 1989 264: 17947-17952
- 96 Bergum PW, Garden SJ. Vampire bat salivary plasminogen activator exhibits a strict and fastidious requirement for polymeric fibrin as its cofactor, unlike human tissue-type plasminogen activator. J Biol Chem 1992; 267: 17726-17731
- 97 Kratzschmar J, Haendler B, Langer G, Boidol W, Bringmann P, Alagon A, Donner P, Schleuning WD. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. Gene 1991; 105: 229-237
- 98 Garden SJ, Hare TR, Bergum PW, Cuca GC, O’NeiU-PaUadino L, Zavodny SM. Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. Blood 1990; 76: 2560-2564
- 99 GardeU SJ, Ramjit DR, Stabilito II, Fujita T, Lynch JJ, Cuca GC, Jain D, Wang S, Tung J, Mark GE, Shebuski RJ. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat saHvary plasminogen activator in rabbits. Circulation 1991; 84: 244-253
- 100 MeUott MJ, Stabilito II, Holahan MA. et al: Vampire bat salivaiy plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombolysis. Arterioscl Thromb 1992; 12: 212-221
- 101 Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992; 79: 1213-1217
- 102 Witt W, Maass B, Baldus B. et al. Coronary thrombolysis with Desmodus salivary plasminogen activator in dogs. Fast and persistent recanalization by intravenous bolus administration. Circulation 1994; 90: 421-426
- 103 Collen D, Lijnen HR. Staphylokinase, afibrin-speciflcplasminogen activator with therapeutic potential. Blood 1994; 84: 680-686
- 104 Lijnen HR, Van HoefB, Vandenbossche L, Collen D. Biochemical properties of natural and recombinant staphylokinase. Fibrinolysis 6: 214-225 1992;
- 105 Collen D, Van HoefB, Schlott B, Hartmann M, Guhrs CH, Lijnen HR. Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. EurJBiochem 1993; 216: 307-314
- 106 Schlott B, Hartmann M, Guhrs KH, Birch-Hirschfeld E, Gase A, Vetteimann S, Collen D, Lijnen HR. Functional properties of recombinant staphylokinase variants obtained by site specific mutagenesis of methionine-26. Biochim Biophys Acta 1994; 1204: 235-242
- 107 Collen D, Van de WerfF. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993; 87: 1850-1853
- 108 Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemostas 1994; 72: 297-301